阿里健康(00241.HK)發新股購母企醫療健康類目營銷權 涉資135億元
阿里健康(00241.HK)公布,向控股股東阿里巴巴(09988.HK)收購AJK Technology全部股權,代價135.12億元,包括現金20億元;及透過發行25.58億股代價股支付,發行價4.5元,較上交易日(29日)收報折讓3.43%。完成後,阿里巴巴於公司持股將由56.99%增至63.83%。
AJK Technology業務主要包括在醫療健康類目下的獨家營銷審核權,即在天貓平台醫療健康類目下,運營及管理營銷審核服務之獨家權利,並絕對排除阿里媽媽集團和淘天集團;向主營類目為醫療健康類目的目標商家提供之增值服務;及阿里媽媽集團通過品銷寶等進行品牌營銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.